Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

por Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje
Publicado 2017

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

por Verheijen, Remy B., Yu, Huixin, Schellens, Jan H.M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D.R.
Publicado 2017

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

por Verheijen, Remy B., Atrafi, Florence, Schellens, Jan H. M., Beijnen, Jos H., Huitema, Alwin D. R., Mathijssen, Ron H. J., Steeghs, Neeltje
Publicado 2017

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

por Tzogani, Kyriaki, Yu, Yang, Meulendijks, Didier, Herberts, Carla, Hennik, Paula, Verheijen, Remy, Wangen, Torunn, Dahlseng Håkonsen, Gro, Kaasboll, Torny, Dalhus, Marianne, Bolstad, Bjorg, Salmonson, Tomas, Gisselbrecht, Christian, Pignatti, Francesco
Publicado 2019

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C

por Yoh, Kiyotaka, Hirashima, Tomonori, Saka, Hideo, Kurata, Takayasu, Ohe, Yuichiro, Hida, Toyoaki, Mellemgaard, Anders, Verheijen, Remy B., Ou, Xiaoling, Ahmed, Ghada F., Hayama, Manabu, Sugibayashi, Ko, Oxnard, Geoffrey R.
Publicado 2021

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial

por Choueiri, Toni K., Heng, Daniel Y. C., Lee, Jae Lyun, Cancel, Mathilde, Verheijen, Remy B., Mellemgaard, Anders, Ottesen, Lone H., Frigault, Melanie M., L’Hernault, Anne, Szijgyarto, Zsolt, Signoretti, Sabina, Albiges, Laurence
Publicado 2020

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer

por Janssen, Julie M., Verheijen, Remy B., van Duijl, Tirsa T., Lin, Lishi, van den Heuvel, Michel M., Beijnen, Jos H., Steeghs, Neeltje, van den Broek, Daan, Huitema, Alwin D. R., Dorlo, Thomas P. C.
Publicado 2022

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma

por Molenaar-Kuijsten, Laura, van Meekeren, Milan, Verheijen, Remy B., Bovée, Judith V. M. G., Fiocco, Marta, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Miah, Aisha B., Gelderblom, Hans, Haas, Rick L. M., Steeghs, Neeltje
Publicado 2021

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

por Verheijen, Remy B., van der Biessen, Diane A. J., Hotte, Sebastien J., Siu, Lillian L., Spreafico, Anna, de Jonge, Maja J. A., Pronk, Linda C., De Vos, Filip Y. F. L., Schnell, David, Hirte, Hal W., Steeghs, Neeltje, Lolkema, Martijn P.
Publicado 2019

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

por de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Publicado 2019